Medical Research and Clinical Trials

EHA 2026: Promising New Avenues Emerge for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment

• Medical Research and Clinical Trials

EHA 2026: Promising New Avenues Emerge for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment

Nila Kartika Wati June 16, 2026

GENEVA, SWITZERLAND – [Date of Publication] – The European Hematology Association (EHA) 2026 Congress has become a...

Read More Read more about EHA 2026: Promising New Avenues Emerge for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment

Unraveling the Silent Risk: Genetics and Treatment Shape Secondary Cancer Threat for Childhood Cancer Survivors

• Medical Research and Clinical Trials

Unraveling the Silent Risk: Genetics and Treatment Shape Secondary Cancer Threat for Childhood Cancer Survivors

Lina Hope June 16, 2026

FOR IMMEDIATE RELEASE ST. JUDE CHILDREN’S RESEARCH HOSPITAL, MEMPHIS, TN – A groundbreaking study published today in...

Read More Read more about Unraveling the Silent Risk: Genetics and Treatment Shape Secondary Cancer Threat for Childhood Cancer Survivors

AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026

• Medical Research and Clinical Trials

AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026

Ali Ikhwan June 16, 2026

Geneva, Switzerland – June 13, 2026 – AvenCell Therapeutics has presented updated clinical results for its investigational...

Read More Read more about AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026

Navigating the Complex Landscape: Why Strategic CDMO Partnerships are Paramount for Biopharma Success

• Medical Research and Clinical Trials

Navigating the Complex Landscape: Why Strategic CDMO Partnerships are Paramount for Biopharma Success

Basiran June 16, 2026

In the rapidly evolving biopharmaceutical industry, the path from scientific breakthrough to patient access is fraught with...

Read More Read more about Navigating the Complex Landscape: Why Strategic CDMO Partnerships are Paramount for Biopharma Success

GLP-1 Receptor Agonists Show Promising Oncology Potential Beyond Metabolic Disease, ASCO 2026 Reveals

• Medical Research and Clinical Trials

GLP-1 Receptor Agonists Show Promising Oncology Potential Beyond Metabolic Disease, ASCO 2026 Reveals

Siti Muinah June 16, 2026

Chicago, IL – June 20, 2026 – The groundbreaking potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), long...

Read More Read more about GLP-1 Receptor Agonists Show Promising Oncology Potential Beyond Metabolic Disease, ASCO 2026 Reveals

Groundbreaking Triple Therapy from Keck Medicine Unlocks New Hope for Glioblastoma Patients, Potentially Extending Survival

• Medical Research and Clinical Trials

Groundbreaking Triple Therapy from Keck Medicine Unlocks New Hope for Glioblastoma Patients, Potentially Extending Survival

Azzam Bilal Chamdy June 15, 2026

LOS ANGELES, CA – [Date of Publication] – A new beacon of hope has emerged for patients...

Read More Read more about Groundbreaking Triple Therapy from Keck Medicine Unlocks New Hope for Glioblastoma Patients, Potentially Extending Survival

Lilly’s Novel JAK2 Inhibitor Shows Promising Early Results in Myelofibrosis, Offering New Hope for Patients

• Medical Research and Clinical Trials

Lilly’s Novel JAK2 Inhibitor Shows Promising Early Results in Myelofibrosis, Offering New Hope for Patients

Ammar Sabilarrohman June 15, 2026

Indianapolis, IN – June 15, 2026 – Eli Lilly and Company has unveiled encouraging Phase I data...

Read More Read more about Lilly’s Novel JAK2 Inhibitor Shows Promising Early Results in Myelofibrosis, Offering New Hope for Patients

Breakthrough in Breast Cancer Care: New Trial Identifies and Eliminates Dormant Cancer Cells, Preventing Recurrence

• Medical Research and Clinical Trials

Breakthrough in Breast Cancer Care: New Trial Identifies and Eliminates Dormant Cancer Cells, Preventing Recurrence

Ali Ikhwan June 15, 2026

PHILADELPHIA, PA – In a landmark advancement poised to redefine post-treatment breast cancer care, a federally funded...

Read More Read more about Breakthrough in Breast Cancer Care: New Trial Identifies and Eliminates Dormant Cancer Cells, Preventing Recurrence

Breakthrough in High-Risk Lymphoma Treatment: Tafa-Len-R-CHOP Shows Significant Promise in Pivotal Trial

• Medical Research and Clinical Trials

Breakthrough in High-Risk Lymphoma Treatment: Tafa-Len-R-CHOP Shows Significant Promise in Pivotal Trial

Lina Irawan June 15, 2026

Incyte’s novel combination therapy, Tafa-Len-R-CHOP, has demonstrated a significant reduction in the risk of disease progression or...

Read More Read more about Breakthrough in High-Risk Lymphoma Treatment: Tafa-Len-R-CHOP Shows Significant Promise in Pivotal Trial

Unlocking Glioblastoma’s Secrets: Rogue DNA Rings Offer Hope for Early Detection and Treatment

• Medical Research and Clinical Trials

Unlocking Glioblastoma’s Secrets: Rogue DNA Rings Offer Hope for Early Detection and Treatment

Lina Irawan June 15, 2026

London, UK & Stanford, USA – September 8, 2023 – In a groundbreaking discovery that could fundamentally...

Read More Read more about Unlocking Glioblastoma’s Secrets: Rogue DNA Rings Offer Hope for Early Detection and Treatment